Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

Study identifier:D8151C00001

ClinicalTrials.gov identifier:NCT04999969

EudraCT identifier:2021-002040-78

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tumours

Medical condition

Locally Advanced or Metastatic Solid Tumours

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD0171, Durvalumab, Gemcitabine, Nab-paclitaxel

Sex

All

Actual Enrollment

126

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 10 Dec 2021
Estimated Primary Completion Date: 07 Oct 2024
Estimated Study Completion Date: 07 Oct 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria